vs
STANDARD BIOTOOLS INC.（LAB）与Paysign, Inc.（PAYS）财务数据对比。点击上方公司名可切换其他公司
Paysign, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$22.8M vs $19.6M），Paysign, Inc.净利率更高（6.0% vs -177.4%，领先183.4%），Paysign, Inc.同比增速更快（45.8% vs -11.5%），Paysign, Inc.自由现金流更多（$47.5M vs $-23.1M），过去两年Paysign, Inc.的营收复合增速更高（31.3% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Paysign, Inc.是一家专业支付解决方案提供商，主打定制化预付卡项目、端到端支付处理服务及数字发放工具，核心服务领域覆盖医疗保健、企业激励与大众消费市场，主要业务和客户群体分布于北美地区。
LAB vs PAYS — 直观对比
营收规模更大
PAYS
是对方的1.2倍
$19.6M
营收增速更快
PAYS
高出57.3%
-11.5%
净利率更高
PAYS
高出183.4%
-177.4%
自由现金流更多
PAYS
多$70.6M
$-23.1M
两年增速更快
PAYS
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $22.8M |
| 净利润 | $-34.7M | $1.4M |
| 毛利率 | 48.5% | 57.7% |
| 营业利润率 | -168.5% | 8.1% |
| 净利率 | -177.4% | 6.0% |
| 营收同比 | -11.5% | 45.8% |
| 净利润同比 | -28.8% | -0.7% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABPAYS
| Q4 25 | — | $22.8M | ||
| Q3 25 | $19.6M | $21.6M | ||
| Q2 25 | $21.8M | $19.1M | ||
| Q1 25 | $40.8M | $18.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $22.1M | $15.3M | ||
| Q2 24 | $22.5M | $14.3M | ||
| Q1 24 | $45.5M | $13.2M |
净利润LABPAYS
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-34.7M | $2.2M | ||
| Q2 25 | $-33.5M | $1.4M | ||
| Q1 25 | $-26.0M | $2.6M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $-26.9M | $1.4M | ||
| Q2 24 | $-45.7M | $697.1K | ||
| Q1 24 | $-32.2M | $309.1K |
毛利率LABPAYS
| Q4 25 | — | 57.7% | ||
| Q3 25 | 48.5% | 56.3% | ||
| Q2 25 | 48.8% | 61.6% | ||
| Q1 25 | 48.4% | 62.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 54.9% | 55.5% | ||
| Q2 24 | 46.1% | 52.9% | ||
| Q1 24 | 53.1% | 52.6% |
营业利润率LABPAYS
| Q4 25 | — | 8.1% | ||
| Q3 25 | -168.5% | 7.3% | ||
| Q2 25 | -118.1% | 7.5% | ||
| Q1 25 | -80.8% | 13.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -120.9% | 4.5% | ||
| Q2 24 | -134.5% | 0.9% | ||
| Q1 24 | -132.2% | -2.0% |
净利率LABPAYS
| Q4 25 | — | 6.0% | ||
| Q3 25 | -177.4% | 10.3% | ||
| Q2 25 | -153.7% | 7.3% | ||
| Q1 25 | -63.8% | 13.9% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | -122.0% | 9.4% | ||
| Q2 24 | -203.3% | 4.9% | ||
| Q1 24 | -70.6% | 2.3% |
每股收益（稀释后）LABPAYS
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.09 | $0.04 | ||
| Q2 25 | $-0.09 | $0.02 | ||
| Q1 25 | $-0.07 | $0.05 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | $-0.07 | $0.03 | ||
| Q2 24 | $-0.12 | $0.01 | ||
| Q1 24 | $-0.27 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $48.5M |
| 总资产 | $539.6M | $276.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABPAYS
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABPAYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABPAYS
| Q4 25 | — | $48.5M | ||
| Q3 25 | $399.7M | $45.8M | ||
| Q2 25 | $424.5M | $42.2M | ||
| Q1 25 | $454.6M | $39.3M | ||
| Q4 24 | — | $30.4M | ||
| Q3 24 | $489.3M | $28.5M | ||
| Q2 24 | $510.3M | $26.9M | ||
| Q1 24 | $577.3M | $25.5M |
总资产LABPAYS
| Q4 25 | — | $276.3M | ||
| Q3 25 | $539.6M | $209.5M | ||
| Q2 25 | $557.0M | $193.9M | ||
| Q1 25 | $579.6M | $205.1M | ||
| Q4 24 | — | $179.0M | ||
| Q3 24 | $681.5M | $167.0M | ||
| Q2 24 | $708.7M | $182.3M | ||
| Q1 24 | $777.7M | $173.0M |
负债/权益比LABPAYS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $48.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $47.5M |
| 自由现金流率自由现金流/营收 | -118.1% | 208.7% |
| 资本支出强度资本支出/营收 | 4.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 35.29× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $51.2M |
8季度趋势，按日历期对齐
经营现金流LABPAYS
| Q4 25 | — | $48.1M | ||
| Q3 25 | $-22.2M | $6.8M | ||
| Q2 25 | $-20.7M | $3.6M | ||
| Q1 25 | $-30.3M | $-6.0M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-27.9M | $-20.2M | ||
| Q2 24 | $-39.0M | $20.6M | ||
| Q1 24 | $-62.5M | $8.2M |
自由现金流LABPAYS
| Q4 25 | — | $47.5M | ||
| Q3 25 | $-23.1M | $6.3M | ||
| Q2 25 | $-22.6M | $3.6M | ||
| Q1 25 | $-35.3M | $-6.1M | ||
| Q4 24 | — | $14.2M | ||
| Q3 24 | $-30.1M | $-20.3M | ||
| Q2 24 | $-41.0M | $20.4M | ||
| Q1 24 | $-63.3M | $8.2M |
自由现金流率LABPAYS
| Q4 25 | — | 208.7% | ||
| Q3 25 | -118.1% | 29.2% | ||
| Q2 25 | -103.6% | 18.6% | ||
| Q1 25 | -86.6% | -32.9% | ||
| Q4 24 | — | 91.0% | ||
| Q3 24 | -136.4% | -133.0% | ||
| Q2 24 | -182.2% | 142.4% | ||
| Q1 24 | -138.9% | 62.1% |
资本支出强度LABPAYS
| Q4 25 | — | 2.6% | ||
| Q3 25 | 4.5% | 2.1% | ||
| Q2 25 | 8.7% | 0.5% | ||
| Q1 25 | 12.4% | 0.4% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | 10.2% | 0.8% | ||
| Q2 24 | 8.6% | 1.0% | ||
| Q1 24 | 1.7% | 0.4% |
现金转化率LABPAYS
| Q4 25 | — | 35.29× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -2.33× | ||
| Q4 24 | — | 10.43× | ||
| Q3 24 | — | -14.03× | ||
| Q2 24 | — | 29.48× | ||
| Q1 24 | — | 26.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
PAYS
| Plasma Industry | $12.6M | 55% |
| Pharma Industry | $9.6M | 42% |
| Other | $558.4K | 2% |
